The trajectory of companies tied to Sildenafil's legacy presents a complex investment picture . While the initial success generated substantial gains, generic competition have significantly diminished sales . Investing in connected pharmaceutical businesses now requires a careful assessment of proprietary safeguards, evolving medical trends , and t